Android Apple

Roche's Columvi shows to offer extended survival in Phase III DLBCL trial

By Yahoo! Finance   |   6 months ago
Roche's Columvi shows to offer extended survival in Phase III DLBCL trial

Roche's Phase III STARGLO trial showed Columvi with GemOx extended survival in relapsed/refractory DLBCL patients. Results indicated a 41% reduction in mortality risk compared to R-GemOx, meeting primary and secondary endpoints.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.